Salt Lake City, UT – According to filings with the U.S. Securities and Exchange Commission, Halia Therapeutics is raising $15,000,000.00 in new funding. Sources indicate as part of senior management Chief Operating Officer, Jared Bearss played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Halia Therapeutics

At Halia Therapeutics we are discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system’s response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses. We use an innovative approach to drug discovery by translating advances in the understanding of the importance of inflammation in human pathologies such as cancer and neurodegenerative diseases. Our scientists have made fundamental discoveries in the fields of oncology, Alzheimer’s disease and other neurodegenerative disorders and we leverage these experiences to identify novel targets to treat these diseases. Founded in 2017, our incredible team of scientists have worked tirelessly to bring Halia Therapeutics to the forefront in the field of inflammation drug discovery. We will continue to work relentlessly to translate our work into new medicines for patients.

To learn more about Halia Therapeutics, visit http://www.haliatherapeutics.com/

Contact:
Jared Bearss, Chief Operating Officer
801-753-5707
jbearss@haliatherapeutics.com
https://www.linkedin.com/in/jared-bearss-30901a10/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved